Delta Air Lines 2002-1G1 Pass-Thru Certificates Upgraded To 'BBB' On Expectation Of Improving Collateral Jun 12

  • ID: 2164838
  • June 2012
  • Standard & Poors
1 of 3

Delta Air Lines is scheduled to repay its 2002-1 Class G2 certificates on July 2, 2012. In conjunction with that scheduled maturity, 15 aircraft will drop out of the collateral pool. We believe asset coverage that the remaining 17 planes provide for the 2002-1 Class G1 certificates, which remain outstanding, will improve. We are raising our rating on the Class G1 certificates to 'BBB' from 'BB+'. NEW YORK (Standard & Poor's) June 28, 2012--Standard & Poor's Ratings Services said today that it raised its rating on Delta Air Lines Inc.'s 2002-1 Class G1 certificates to 'BBB' from 'BB+'. "The upgrade reflects our expectation of improved asset coverage for the 2002-1 Class G1 certificates after Delta repays the G2 certificates," said...

Companies mentioned in this report are:
- Delta Air Lines Inc.

Action: Upgraded

Standard and Poors RatingsXpress Credit Research provides in-depth coverage of international corporates, financial institutions, insurance companies, utilities, sovereigns and structured finance programs. RatingsXpress Credit Research lets users determine the credit rating of holdings and identify key factors underlying an issuer's creditworthiness, distinguishes the different risk exposures for new and existing deals, and provides an understanding of how their analysts interpret key regulatory, political and environmental events and their economic impact.

Research type: News
This product is a is a brief one-page announcement of no more than 500 words with a quote from the analyst. It is media and investor focused with no accompanying commentary article.

Note: Product cover images may vary from those shown
2 of 3

- Delta Air Lines Inc.

Note: Product cover images may vary from those shown
3 of 3
Note: Product cover images may vary from those shown




Our Clients

  • Fluidigm Corporation
  • Apple, Inc.
  • CEVA Santé Animale
  • Abbott Laboratories Ltd.
  • Merck Group
  • Allergan Inc.
  • Pfizer Inc.